Cart is empty The U.S. Food and Drug Administration has approved the humanized monoclonal antibody Zynyz (retifanlimab-dlwr) as the first first-line treatment for advanced anal cancer.
The U.S. Food and Drug Administration has approved the humanized monoclonal antibody Zynyz (retifanlimab-dlwr) as the first first-line treatment for advanced anal cancer.
Leave A Comment